BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34606270)

  • 21. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).
    Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G
    Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
    Narayanan S; Wu ZX; Wang JQ; Ma H; Acharekar N; Koya J; Yoganathan S; Fang S; Chen ZS; Pan Y
    Int J Biol Sci; 2021; 17(10):2652-2665. PubMed ID: 34326700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.
    Stefan K; Schmitt SM; Wiese M
    J Med Chem; 2017 Nov; 60(21):8758-8780. PubMed ID: 29016119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
    Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-Carboranylquinazoline: The Path to an ABCG2 Inhibitor.
    Stockmann P; Kuhnert L; Zörner L; Honscha W; Hey-Hawkins E
    ChemMedChem; 2023 Jun; 18(11):e202300094. PubMed ID: 36988057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
    Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
    PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
    Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
    Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
    Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
    Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.
    Ni Z; Bikadi Z; Shuster DL; Zhao C; Rosenberg MF; Mao Q
    Biochemistry; 2011 Sep; 50(37):8057-66. PubMed ID: 21854076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of ABCG2/BCRP-Mediated Multidrug Resistance by 5,3',5'-Trihydroxy-3,6,7,4'-Tetramethoxyflavone Isolated from the Australian Desert Plant
    Petersen MJ; Lund XL; Semple SJ; Buirchell B; Franzyk H; Gajhede M; Kongstad KT; Stenvang J; Staerk D
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
    Ahmed-Belkacem A; Pozza A; Macalou S; Pérez-Victoria JM; Boumendjel A; Di Pietro A
    Anticancer Drugs; 2006 Mar; 17(3):239-43. PubMed ID: 16520651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.